

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Cenobamate for adjunctive treatment of focal epilepsy ID1553

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Arvelle Therapeutics (cenobamate) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Brain and Spine Foundation • Brain Charity • Epilepsy Action • Joint Epilepsy Council • Muslim Council of Britain • Neurological Alliance • South Asian Health Foundation • Specialised Healthcare Alliance • S.T.A.B.L.E (Supporting those Affected by Lifelong Epilepsy) • SUDEP Action • Sue Ryder • Young Epilepsy <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists • British Geriatrics Society • British Neuropathological Society • British Paediatric Epilepsy Group • Epilepsy Nurses Association • Epilepsy Society • Institute of Neurology • International League Against Epilepsy UK • Neuromodulation Society of UK and Ireland • Primary Care Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • Neurological Alliance of Scotland • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Neurological Alliance • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord-UK (gabapentin, lamotrigine, levetiracetam, phenobarbital, topiramate, zonisamide, pregabalin) • ADVANZ Pharma (acetazolamide, phenytoin sodium) • Atnahs Pharma (clobazam) • Auden Mckenzie (clobazam, phenytoin sodium) • Aurobindo (gabapentin, lamotrigine, levetiracetam, phenytoin, topiramate) • Bowmed Ibisqus (levetiracetam) • Brown & Burke (gabapentin) • Desitin Pharma (levetiracetam, sodium valproate)

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Knowsley CCG • NHS Sandwell and West Birmingham CCG • Welsh Government 	<ul style="list-style-type: none"> • Eisai (eslicarbazepine acetate, perampanel, zonisamide) • Endo Ventures (zonisamide) • GlaxoSmithKline (lamotrigine) • Janssen-Cilag (topiramate) • M & A Pharmachem (gabapentin) • Martindale Pharma (clobazam, phenobarbital) • Mylan (carbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate) • Novartis (carbamazepine, oxcarbazepine) • Pfizer (gabapentin, phenytoin, pregabalin) • Rosemont Pharmaceuticals (clobazam, clonazepam, gabapentin, levetiracetam, topiramate) • Sanofi (clobazam, sodium valproate, valproic acid, vigabatrin) • Scieure Pharma (levetiracetam) • SERB Laboratories (primidone) • Teva UK (tiagabine) • Thame Laboratories (clobazam, clonazepam, gabapentin, levetiracetam) • UCB Pharma (brivaracetam, lacosamide, levetiracetam) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Brain Research UK • British Neurological Research Trust • Cochrane Epilepsy Group • Epilepsy Research UK • Genomics England • MRC Clinical Trials Unit • National Hospital for Neurology and Neurosurgery • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.